35 related articles for article (PubMed ID: 32647353)
1. Clinical opportunities in combining immunotherapy with radiation therapy.
Finkelstein SE; Fishman M
Front Oncol; 2012; 2():169. PubMed ID: 23233905
[TBL] [Abstract][Full Text] [Related]
2. The role of immunotherapy in prostate cancer: an overview of current approaches in development.
Risk M; Corman JM
Rev Urol; 2009; 11(1):16-27. PubMed ID: 19390671
[TBL] [Abstract][Full Text] [Related]
3. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
5. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU
Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
Philipson RG; Romero T; Wong JK; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Valle L; Chong N; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Klein EA; Tosoian JJ; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Kupelian PA; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Kishan AU
Eur Urol; 2021 Aug; 80(2):142-146. PubMed ID: 33985797
[TBL] [Abstract][Full Text] [Related]
7. Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer.
Adorno Febles VR; Blacksburg S; Haas JA; Wise DR
Front Oncol; 2020; 10():830. PubMed ID: 32670868
[TBL] [Abstract][Full Text] [Related]
8. Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.
Erlandsson A; Lundholm M; Watz J; Bergh A; Petrova E; Alamdari F; Helleday T; Davidsson S; Andren O; Tarish F
Int J Immunopathol Pharmacol; 2023; 37():3946320231158025. PubMed ID: 36880147
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers.
Cheema AK; Li Y; Ventimiglia M; Kowalczyk K; Hankins R; Bandi G; Janowski EM; Grindrod S; Villagra A; Dritschilo A
Clin Cancer Res; 2023 Mar; 29(5):921-929. PubMed ID: 36508164
[TBL] [Abstract][Full Text] [Related]
10. Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.
Karwacki J; Kiełbik A; Szlasa W; Sauer N; Kowalczyk K; Krajewski W; Saczko J; Kulbacka J; Szydełko T; Małkiewicz B
Cells; 2022 Sep; 11(18):. PubMed ID: 36139368
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer.
Hu W; Pei Y; Ning R; Li P; Zhang Z; Hong Z; Bao C; Guo X; Sun Y; Zhang Q
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4533-4545. PubMed ID: 36138265
[TBL] [Abstract][Full Text] [Related]
12. Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention.
Huang L; LaBonte MJ; Craig SG; Finn SP; Allott EH
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326519
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.
Liveringhouse C; Sim A; Yamoah K; Poch M; Wilder RB; Pow-Sang J; Johnstone PAS
Rep Pract Oncol Radiother; 2021; 26(2):188-195. PubMed ID: 34211768
[TBL] [Abstract][Full Text] [Related]
14. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
15. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.
Nickols NG; Ganapathy E; Nguyen C; Kane N; Lin L; Diaz-Perez S; Nazarian R; Mathis C; Felix C; Basehart V; Zomorodian N; Kwak J; Kishan AU; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Chu FI; Romero T; Elashoff D; Reiter RE; Schaue D
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):135-139. PubMed ID: 32647353
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
17. Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT.
Kane N; Romero T; Diaz-Perez S; Rettig MB; Steinberg ML; Kishan AU; Schaue D; Reiter RE; Knudsen BS; Nickols NG
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):207-209. PubMed ID: 35058580
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
